A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly
Notes for this study:
| Effect | Increase |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 54 |
| Sex | Both Genders |
| Age Range | 65+ |
Supplementation of EGb-761 daily over the course of 3 months in elderly persons experiencing cognitive decline but not diagnosed with dementia or other neurodegenerative diseases noted improvements in cognition and reaction time relative to placebo.
